CHMP gennemgik alle de oplysninger, som indehaverne af markedsføringstilladelserne havde indsendt om benefit/ risk- forholdet for oral moxifloxacin til de ovenstående indikationer.
The CHMP reviewed all of the information made available by marketing authorisation holders (MAH) on the balance of benefits and risks of oral moxifloxacin in the above indications.